India faces a potential shortage of the polio vaccine following the shutdown of Sanofi plants. However, Sanofi has assured that there will be no interruption in the availability of its inactivated polio vaccine (IPV) in India, despite recently discontinuing ShanIPV, as reported by BShajan. This comes amidst a broader restructuring by Sanofi, involving global layoffs as part of a "full pipeline reprioritization", as communicated by R&D chief Houman Ashrafian. In response to concerns about vaccine availability, Serum Institute CEO Adar Poonawalla has stated that there cannot be a shortage of the polio vaccine, as the Serum Institute can produce it.
Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff $SNY https://t.co/aYSoQWZZhG
There can't be #shortage of #Polio #vaccine; #SerumInstitute can make it: #CEO #AdarPoonawalla https://t.co/fegrjTnbeI
Sanofi is laying off employees around the globe after a "full pipeline reprioritization," R&D chief Houman Ashrafian told staff in an email Thursday that was obtained by Fierce Biotech. https://t.co/X7hEA1iW9D
After the French drugmaker Sanofi India Limited recently discontinued ShanIPV, its inactivated polio vaccine (IPV), in India, the company has confirmed that it will ensure there is no interruption in the availability its IPV vaccine, @BShajan reports. https://t.co/cjBnGE84wo
After #Sanofi recently discontinued ShanIPV, its inactivated #polio vaccine, in India, the company has confirmed that it will ensure there is no interruption in the availability its IPV vaccine https://t.co/MvLLS6r3Ky
#Polio #vaccine #shortage looms over #India with #Sanofi plants' #shutdown https://t.co/m5Er2cpFRs